RATIONALE: Cutaneous (CM) and systemic mastocytosis (CM) are rare clinical entities that cause symptoms that are debilitating and may be lifethreatening. We examined factors associated with anaphylaxis in these two populations. METHODS: Data were extracted from the records of patients diagnosed with CM and SM by 2016 WHO criteria. Variables of interest included sex, age, cutaneous involvement, cardiorespiratory diseases, atopic family history and tryptase level. Anaphylaxis severity was graded using the scale reported by Brown (2004). Clinical variables associated with anaphylaxis were analyzed using chi-squared and/or two-tailed T-tests as appropriate. RESULTS: Fifty-six patients were included in the analysis (15 with CM, 41 with SM) of whom 30 had anaphylaxis. Atopic family history (n553, p5.037) and cutaneous involvement (n556, p50419) were inversely correlated with increased risk of anaphylaxis. Higher tryptase levels were inversely correlated in patients with anaphylaxis (mean5 26. University of Virginia School of Medicine, Charlottesville, VA. RATIONALE: Milk and wheat have been implicated in numerous nonIgE mediated diseases, including eosinophilic esophagitis, gastrointestinal intolerance, and autism spectrum disorder, but the underlying mechanism is unknown. Beta-casomorphin 7 (BCM7) is an opioid receptor agonist peptide generated from milk of ''A1'' cattle, and gliadorphin (G7) is the gluten homologue. While BCM-7 has been shown to stimulate rat peritoneal mast cells, this has not been reported in humans, nor with G7. METHODS: LUVA mast cells were incubated with commerciallyavailable BCM7 and G7 at increasing concentrations (0.001pg/ml-10pg/ ml) and times (30min-24hrs). PGD2 was measured by ELISA as a marker of mast cell degranulation. Similar conditions were used to stimulate mast cells differentiated from CD34+ hematopoietic cells. RT PCR and flow cytometry were used to determine expression of MRGPRX2 on LUVA cells. RESULTS: PGD2 release increased in LUVA and peripherally-differentiated mast cells incubated with BCM7 and G7 compared to negative controls. For BCM-7, the optimal conditions were 0.1mg/ml for 3 hours (507pg/ml vs 142pg/ml) and for G7, 0.1mg/ml for 6 hours (212pg/ml vs 69pg/ml). LUVA cells expressed MRGPRX2. CONCLUSIONS: We demonstrate that BCM7 and its homologue, G7, stimulate mast cell degranulation as measured by PGD2 release in an immortal mast cell line and in peripherally-differentiated mast cells. It is possible this occurs through the MRGPRX2 receptor, a recently described G-coupled protein receptor on mast cells that recognizes opiates, which has been implicated in non-IgE mediated allergic-type responses. Further investigations into the mechanism of activation with LUVA and MRGPRX2 reporter cell lines are warranted. Center for Cough, Largo, FL. RATIONALE: Secondary causes of mast cell activation syndrome (MCAS) include multiple entities. Tryptase is a biomarker for mast cell disease. Incidence of elevated tryptase is unknown in patients with tumors of neuroectodermal origin. Here we present an adult with elevated tryptase with evidence of MCAS and a diagnosis of Pancreatic Neuroendocrine Tumor (PanNET). METHODS: Serum Tryptase, Endoscopic Ultrasound(EUS) biopsy and octreotide scan RESULTS: A 69-year-old male was evaluated for episodes of hives, diaphoresis, hypertension and tachycardia requiring hospitalizations. Triggers included stings from wasps and fire ants. SPT was positive and subcutaneous immunotherapy was started. However, during build-up, patient reported dizziness, mind fogginess, hypertension and tachycardia with improvement after IM epinephrine. Other episodes were similar but no clear triggers were identified. Physical examinations were normal except anxious appearance. Tryptase was 27 ng/mL during symptoms, no change from baseline. These episodes occurred for a few years, but his reactions started to include flushing, abdominal cramping with diarrhea. Further investigation showed a negative bone marrow, elevated urine HIAA, 12.7mg/24 h (ref:<6 mg/24h), and elevated chromogranin A, 572 A ng/ml (ref range 25-140 ng/ml). Octreotide scan showed focal area of uptake in the tail of the pancreas consistent with MRI findings of a mass. EUS biopsy of lesion confirmed pancreatic neuroendocrine tumor. CONCLUSIONS: Elevated tryptase in the peripheral blood may be associated with PanNET or MCAS may be triggered by the presence of PanNET. In addition, episodes showed improvement with IM epinephrine over many years. Once the PanNET is resected and we will reassess his tryptase.
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